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Clinical Implications 38 
The proposed asthma prediction tool is simple and uses information that is non-39 
invasive and easy to assess. This makes it an ideal instrument for use in clinical 40 
practice and research. 41 
 42 
Capsule summary  43 
We have developed a simple tool to predict later asthma in preschool children 44 
suffering from wheeze or cough. Its simplicity and internal validity facilitate use in 45 
clinical practice and epidemiological research. 46 
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Abstract 54 
Background: Many preschool children suffer from wheeze or cough, but only some 55 
have asthma later. Existing prediction tools are difficult to apply in clinical practice or 56 
exhibit methodological weaknesses.  57 
Objective: To develop a simple and robust tool for predicting asthma at school-age 58 
in pre-school children with wheeze or cough.   59 
Methods: From a population-based cohort in Leicestershire, UK, we included 1-3 60 
year-olds seeing a doctor for wheeze or cough, and assessed prevalence of asthma 61 
five years later. We considered only non-invasive predictors that are easy to assess 62 
in primary care: demographic and perinatal data, eczema, upper and lower 63 
respiratory symptoms and family history of atopy. We developed a model using 64 
logistic regression, avoided over-fitting with LASSO-penalty, and then simplified it to 65 
a practical tool. We performed internal validation and assessed its predictive 66 
performance using the scaled Brier score and the area under receiver operating 67 
characteristic curve (AUC).   68 
Results: Of 1226 symptomatic children with follow-up information, 345 (28%) had 69 
asthma 5 years later. The tool consists of 10 predictors yielding a total score 70 
between 0 and 15: sex, age, wheeze without colds, wheeze frequency, activity 71 
disturbance, shortness of breath, exercise-related and aeroallergen-related 72 
wheeze/cough, eczema, and parental history of asthma/bronchitis. The scaled Brier 73 
scores for the internally validated model and tool were 0.20 and 0.16, and the AUCs 74 
were 0.76 and 0.74, respectively.  75 
Conclusion:  76 
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This tool represents a simple, low-cost and non-invasive method to predict the risk 77 
for later asthma in symptomatic pre-school children, which is ready to be tested in 78 
other populations.  79 
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Introduction  80 
Many preschool children present to primary care with recurrent wheeze or cough. 81 
These symptoms are a burden to families and lead to treatment with inhalers, 82 
antibiotics or cough mixtures, hospitalizations and considerable health care costs.1 In 83 
this age-group, wheezing illness is heterogeneous and includes different phenotypes 84 
with varying prognoses.2-5 Fortunately, only some children will have persistent 85 
problems till school-age. The ability to predict persistence of wheeze up to school-86 
age would allow preventative and therapeutic efforts to be directed to those most in 87 
need6 and would reassure parents of children with transient problems. It would also 88 
help to select children for intervention studies aiming to alter the course of disease.7 89 
Several groups have presented tools for prediction of later asthma in preschool 90 
children8-16, but their use for primary care is limited.17 Some tools were developed in 91 
study populations untypical for primary care. For instance, they included 92 
asymptomatic children,8, 10, 14, 16 children with mild symptoms, who never visited their 93 
doctor,13, 15 or only high-risk children hospitalized for bronchiolitis.12 Several studies 94 
excluded children with chronic cough,13, 15 who might actually suffer from a variant of 95 
asthma.4, 18 Some tools included predictors, such as parental education, that are not 96 
easily generalizable to other populations.9 Other tools involve invasive 97 
measurements (blood tests or skin prick tests) that might not be accepted by all 98 
families in primary care.8, 11, 13, 14 Finally, the methods commonly used to develop the 99 
prediction tools are prone to over-fitting the data.9, 11, 13 Over-fitting leads to reduced 100 
performance when tools are applied to other populations.19, 20  101 
In this study we aimed to develop a simple tool to predict asthma at school-age in 102 
preschool children with wheeze or chronic cough. We designed the tool for 103 
application in clinical practice, particularly primary care, by: a) studying a population 104 
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of symptomatic children, who had presented to the doctor for wheeze or cough; b) 105 
defining a clinically relevant outcome; c) considering only predictive factors easily 106 
assessed during a single consultation (a detailed symptom history, but no blood or 107 
skin prick tests and no repeated observations); d) developing a robust model that 108 
performs well in internal validation and relevant sensitivity analyses but does not 109 
over-fit the data and is therefore likely to be transferable to other populations.  110 
 111 
Methods 112 
Study population 113 
We analyzed data from a population-based childhood cohort from Leicestershire, 114 
UK, described in detail elsewhere.21, 22, 23 In brief, we recruited a representative 115 
population-based sample of 6808 children of white and south Asian ethnic origin, 116 
born in 1993-97. Perinatal data were collected at birth; data on growth and 117 
development were acquired prospectively during childhood. Upper and lower 118 
respiratory morbidity, treatments and health care utilization, family history of atopic 119 
disease and individual and family-related exposures were assessed by repeated 120 
questionnaires (1998, 1999, 2001, 2003, 2006, 2010). The study was approved by 121 
the Leicestershire Health Authority Research Ethics Committee. 122 
Presentation at baseline (inclusion criteria) 123 
Our analysis included all cohort children aged 1-3 years at baseline with parent-124 
reported wheeze or chronic cough (cough without colds or cough at night) with one 125 
or more visits to the doctor for wheeze or cough during the past 12 months (Fig 1, 126 
highlighted in grey). The original questions are provided in the online repository. We 127 
included chronic cough, because some children with chronic cough might suffer from 128 
a variant of asthma and be at risk for asthma later in life.4, 18 Information on 129 
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symptoms at baseline was taken from the 1998 or the 1999 questionnaire, favoring 130 
the questionnaire when children were closest to age 2.0 years.  131 
Any asthma at school-age (definition of outcome) 132 
We defined a clinically relevant outcome as the combination of current wheeze plus 133 
use of asthma medication during the past 12 months at the age of 6-8 years, i.e. 5 134 
years later (see online repository for original questions). Asthma medication included 135 
short- or long-acting beta-2-agonists, inhaled corticosteroids, leukotriene receptor 136 
antagonists or oral corticosteroids.  137 
We used Fisher’s exact test to compare characteristics of children with and without 138 
the outcome (Table E1, Table I) as well as to compare characteristics of children by 139 
availability of follow-up information (Table E2). Choice of potential predictive factors 140 
We used the following approach to compile the list of potential predictors. First, we 141 
reviewed the literature to identify relevant risk factors for incidence or persistence of 142 
childhood asthma.3, 24-31 From these, we only selected factors that are readily 143 
available in primary care and do not require repeated observations or additional 144 
investigations like blood or skin prick tests. The final list contained 24 potential 145 
predictors (Table E1): demographic and perinatal data; eczema; upper and lower 146 
respiratory symptoms, particularly those reflecting triggers and severity of wheeze; 147 
and parental history of wheeze, asthma, bronchitis or hay fever (see online 148 
repository for original questions). We did not include environmental or 149 
socioeconomic information, because their prevalence and interpretation is likely to 150 
vary between populations and, thus, their inclusion might reduce the generalizability 151 
of the tool. 152 
Model development 153 
We used LASSO-penalized logistic regression to develop the prediction model.32, 33  154 
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This approach allows to identify important predictors and to estimate their influence 155 
on later asthma without over-fitting the data. Traditional methods used for selecting 156 
predictors, such as stepwise backward or forward selection, tend to over-fit the data, 157 
resulting in models that predict outcomes in the current dataset well, but become 158 
unreliable in other datasets.20 For our analysis, we recoded all potential predictors 159 
with >2 response categories into multiple binary variables. Thus, 38 binary variables 160 
derived from the 24 questions entered the variable selection process (see online 161 
repository for details). LASSO regression selects predictors in the order of their 162 
predictive importance. The final prediction model allows calculation of a prediction 163 
score and the probability of later asthma for each child. 164 
Model performance 165 
We assessed our prediction model in terms of overall performance, discrimination 166 
and calibration. To assess overall performance we calculated the scaled Brier 167 
score,20 a measure of the discrepancy between the predicted probability and the 168 
actual outcome. A scaled Brier score with a value of zero means that the model does 169 
not predict later asthma in an individual better than if it had been informed only by 170 
the average prevalence of asthma at school-age; the maximal value of one indicates 171 
perfect prediction. To determine the discriminative ability of the model (i.e. its ability 172 
to distinguish between children with and without later asthma) we plotted the receiver 173 
operating characteristics (ROC) curve and calculated the area under this curve 174 
(AUC), also known as c-statistic.20, 34 The AUC can take on values from 0 to 1, with 1 175 
being a perfectly discriminating model. Discrimination is considered not better than 176 
chance if AUC=0.5, moderate if AUC is 0.6 to 0.8, and good if AUC>0.8.34 177 
Calibration of the model (how well the predicted probabilities agree with the 178 
prevalence of the outcome in subgroups of children) was tested using the Hosmer-179 
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Lemeshow goodness-of-fit-test (HL test)20, 35 and visualized using a calibration plot.20 180 
An HL test result of less than 0.05 indicates that the predicted probabilities and the 181 
actual outcome agree poorly. In the calibration plot, a perfect calibration curve would 182 
lie exactly on the diagonal line. 183 
Internal validity 184 
A prediction model can be validated internally to provide a more accurate estimate of 185 
model performance in other populations. As an internal validation of our model, we 186 
used the leave-one-out cross-validation method20, 34 assessing overall performance 187 
(Brier), discrimination (AUC), and calibration (see online repository for further 188 
explanations). 189 
Sensitivity analyses 190 
To test the robustness of the model developed in our original study population (P0), 191 
we performed sensitivity analyses using modified inclusion criteria at baseline or 192 
modified definitions of the outcome, resulting in slight changes of the study 193 
populations (P1 to P4, described in more detail in Tables E3 and E4 of the online 194 
repository). 195 
We first applied our existing prediction model to these modified populations and 196 
calculated the scaled Brier score and AUC (Sensitivity analysis I). Second, we 197 
developed new models within the slightly modified study populations P1 to P4, and 198 
assessed their performance (Sensitivity analysis II).  199 
Clinical prediction tool 200 
To simplify our model to a practical tool, we considered three different approaches: 201 
a) multiplying regression coefficients by factors 10, 5 and 3 and rounding them to the 202 
nearest integer;20 b) setting the penalty of the LASSO-penalized logistic regression 203 
so that only a few important predictors (5 or 3) were retained, and c) considering a 204 
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model with frequency of wheeze as the only predictor.19 All these approaches aimed 205 
to reduce the number of variables while maintaining a comparable predictive 206 
performance. 207 
 208 
Results 209 
Study population 210 
At the baseline survey, 5878 of 6808 children were aged 1-3 years. Figure 1 shows 211 
how many of the 1-3 year old children reported episodes of wheeze, cough without 212 
colds or cough at night in the past 12 months and in addition reported visits to a 213 
doctor (N=2444), making them eligible for the study. For 1226 we had information on 214 
any asthma five years later. Their characteristics are shown in Table I for the 215 
variables selected by the main model and in Table E1 (online repository) for all 216 
potential predictors considered. At baseline, 336 children (27.4%) were aged one 217 
year, 702 (57.3%) two years and 188 (15.3%) three years. The mean prediction 218 
interval from baseline to outcome was 4.5 (± SD 0.5) years. At school-age, 345 219 
(28.1%) had any asthma. 220 
Table E2 in the online repository compares eligible children with and without follow-221 
up information. The groups were comparable in many aspects (chronic cough, upper 222 
respiratory infections, eczema and parental history), but those with follow-up 223 
information were more likely to be of white ethnicity and less likely to have wheeze at 224 
baseline. 225 
Main prediction model 226 
Of the 38 binary predictors that entered variable selection, the LASSO-penalized 227 
logistic regression retained 22 (Table II). The 5 most important predictors were, in 228 
order of importance, shortness of breath, frequent wheeze, wheeze without colds, 229 
Pescatore 12 
 
activity disturbance by wheeze and wheeze/cough triggered by exercise. In addition, 230 
the model included aeroallergen-related wheeze/cough, male sex, age, birth weight, 231 
gestational age, eczema, upper respiratory symptoms, and parental history of 232 
wheeze, asthma, bronchitis or hay fever.  233 
In the original study population, the overall performance of the main model measured 234 
by the scaled Brier score was 0.23 and its discriminative ability (AUC) was 0.78. In 235 
internal validation, these measures were comparable, 0.20 and 0.76 respectively. 236 
The calibration plot (Fig 2) shows good agreement between the predicted 237 
probabilities of later asthma and the observed frequencies in internal validation. The 238 
same was indicated by the Hosmer-Lemeshow test (p=0.6).  239 
Sensitivity analyses 240 
Sensitivity analyses I: The main model was robust to changes in baseline criteria 241 
(P1, P2 in Table E3). When the outcome definition was changed to wheeze plus a 242 
doctor’s diagnosis of asthma (P3) or to moderately severe asthma (≥4 attacks plus 243 
inhaled corticosteroids; P4), the AUC improved to 0.80 and 0.87 respectively (P3 244 
and P4 in Table E3). Sensitivity analyses II: The performance of new models 245 
developed in these alternative study populations was comparable to the main model 246 
for P1-P3 and slightly improved for P4 (Table E4). The selected predictors and 247 
estimated coefficients in the newly developed models (Table E5) were comparable to 248 
those of the main model.  Severity-related predictors (wheeze without colds, frequent 249 
attacks, shortness of breath, activity disturbance) gained comparatively more weight 250 
when predicting moderately severe asthma (P4).  251 
Clinical prediction tool 252 
We then simplified the model using the three planned approaches. Our preferred 253 
simplification includes 10 variables (13 binary predictors), each of which contributes 254 
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with one of 3 values (1, 2 or 3) to the prediction score (Fig 3; an online version of the 255 
prediction tool is available on www.leicestercohorts.org).  256 
This tool was derived from the original model by multiplying all regression 257 
coefficients with 3 and rounding them to the nearest integer, dropping variables with 258 
coefficients rounded to zero.20 It had almost the same discriminative ability 259 
(AUC=0.775) as the main model (AUC=0.782) (Fig.4). Other approaches to 260 
simplification retained more predictors (making the tool complicated with little benefit) 261 
or had reduced discriminative ability (Table E6), particularly the model with 262 
frequency of wheeze only. 263 
In internal validation, the prediction tool showed only a minor decrease in 264 
performance compared to the main model: the scaled Brier score was 0.16 and the 265 
AUC 0.74.  266 
The maximum score a child can attain using the prediction tool is 15, corresponding 267 
to a 95% probability of having any asthma 5 years later (Fig 3). Sensitivity and 268 
specificity of the tool are 0.72 and 0.71 for a score of 5, and 0.22 and 0.98 for a 269 
score of 10 (additional performance measures are reported in Table E7). In our study 270 
sample, 840 (69%) children were at low risk (score ≤5), 288 (23%) at medium risk 271 
(score ≥6 and ≤9) and 98 (8%) at high risk (score ≥10) of any asthma 5 years later. 272 
The percentage of children with any asthma at school age was 16%, 48% and 79% 273 
in the low, medium and high risk groups respectively.  274 
 275 
Discussion  276 
Summary of findings 277 
We have developed a new tool for predicting asthma at school-age in preschool 278 
children who see a doctor for wheeze or cough. Our tool includes 10 predictors 279 
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representing wheeze severity and triggers, male sex, age, eczema and parental 280 
respiratory history. It showed good internal validity and is distinguished by ease of 281 
use in primary care and epidemiological studies. 282 
Comparison with previous prediction models 283 
Several prediction models have been proposed for estimating the risk of persistent 284 
asthma in preschool children.8-16 Table III summarizes inclusion criteria, outcome, 285 
methods used to derive the tool, predictors and performance for three tools that used 286 
a similar prediction interval as ours and had a sample size of >300. In short, Castro-287 
Rodriguez (Tucson Children’s Respiratory Study) used data from 2-3 year-olds with 288 
and without respiratory symptoms to develop two prediction tools for asthma at 289 
school-age (loose and stringent asthma predictive index, API; Table III).8 290 
Kurukulaaratchy (Isle of Wight birth cohort) proposed a score for persistence of early 291 
wheeze up to age 10.13 Caudri (PIAMA birth cohort), developed a clinical risk score 292 
for 0-4 year-olds with wheeze or cough to predict asthma at age 7-8.9  293 
The performance of these tools was comparable or slightly less than ours (Table III), 294 
with a Youden index36 (sensitivity + specificity -1) varying from 0.328 to 0.3813 295 
(calculated based on the maximal sum of sensitivity and specificity reported in the 296 
respective studies) compared to 0.43 in our study. The Youden index ranges 297 
between 0 and 1. Values close to 1 indicate large predictive effectiveness and values 298 
close to 0 limited effectiveness.  299 
The method used to derive the APIs is difficult to replicate,8 while methods used for 300 
the other tools 9, 13 (logistic regression with stepwise variable selection) tend to over-301 
fit the data, i.e. the models might be overly influenced by the random variation in the 302 
data used to develop them. This limits the application of the models to other 303 
populations.  304 
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Only Caudri et al. performed an internal validation of their prediction model and 305 
reported a similar AUC (0.72) to the one we obtained (0.74). They included 8 306 
predictors with exact regression coefficients, while our model includes 10 predictors 307 
with simplified regression coefficients that facilitate calculation of individual risks in a 308 
clinical setting. The PIAMA risk score and the API have been tested in a small 309 
external population.19, 37  310 
In comparison to our tool, previous asthma prediction rules included at most two 311 
descriptors of wheeze (out of frequency, duration or wheeze without colds).8-10, 14 In 312 
addition, they relied on blood or skin prick tests,8, 11-13, 15 which are more time 313 
consuming, costly and cumbersome than a detailed symptom history. 314 
Socioeconomic position is a proxy measure for a variety of exposures and health 315 
care access and might have a variable impact in different populations. 9 316 
Strengths and limitations 317 
The main strengths of our tool are the objective approach used for its development 318 
and its clinical applicability. We used a population-based sample of an adequate size 319 
to develop the model. We included only children with health care visits for wheeze or 320 
cough, assuring that the sample represents a clinically relevant population. We 321 
defined a clinically relevant outcome measure (wheeze needing treatment). When 322 
defining a more severe outcome (moderately severe asthma, defined as ≥4 attacks 323 
per year and inhaled corticosteroid treatment) the tool performed even better. All 324 
predictors are obtained routinely when taking a respiratory history for a child 325 
presenting with chronic cough or wheeze and predictors are easy to assess even 326 
during a short primary care consultation or in a questionnaire survey. We used a 327 
method that minimizes over-fitting and is less affected by sampling variability 328 
compared to stepwise variable selection procedures,38 and we did an internal 329 
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validation. Finally, our model predicts a range of probabilities rather than predicting 330 
only a low or high risk as the API.8  331 
Like other studies,8, 9, 11, 13 ours relies on parent-reported questionnaire data. 332 
However, it uses standardized questions, mostly from the ISAAC-study39 and reflects 333 
to some extent the clinical situation, where parents report respiratory symptoms. The 334 
applied questionnaire showed good repeatability.40 We did not use objective 335 
measurements to define our outcome. However, for a subsample of our study 336 
population (N=451), we assessed bronchodilator response in a later survey 337 
conducted in 2006 (Table E8). Using the same outcome definitions (any asthma and 338 
moderately severe asthma), mean percent change in forced expiratory volume in the 339 
1st second (FEV1) was significantly higher in children with any asthma compared to 340 
those without (5.5% (95% CI 3.6-7.3) vs 2.6% (2.0-3.2), p<0.001). For maximal 341 
expiratory flow at 50% of vital capacity (MEF50), mean percent change was 16.7% 342 
(12.8-20.5) and 10.7% (8.8-12.5) respectively (p=0.003). This is less than the cut-343 
offs recommended for clinical situations.41 However, our measurements came not 344 
from hospital-based children referred when they were unwell, but from community-345 
based children with very mild asthma who were usually asymptomatic when 346 
measured. Our results are in line with data from Galant et al, where bronchodilator 347 
responses for FEV1 were 7.3% (4.2-10.4) in mild persistent asthmatics and 7.6% 348 
(5.8-9.5) in mild intermittent asthmatics compared to 2.2% (0.2-4.3) in non-349 
asthmatics.42 Children with and without follow-up information were comparable 350 
(Table E2), although we cannot exclude that selection bias has affected the 351 
composition of the final model. Finally, we interpreted missing values in potential 352 
predictor variables as an absence of the respective risk factor, which may also have 353 
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affected the results. However, the number of missing values did not exceed 5.8% in 354 
any of the potential predictor variables. 355 
Meaning of the study 356 
Our model was robust and results changed little with modifications of the inclusion 357 
criteria and outcomes. In fact, the performance improved (AUC 0.89 vs. 0.78) when 358 
we predicted moderately severe asthma, rather than any asthma. After internal 359 
validation, the AUC of main model and tool were similar to the ones before 360 
validation, suggesting that there was little over-fitting.  361 
Our tool used only information on symptoms that can be gathered in a simple 362 
patient’s history. Despite that, it had a similar or better predictive performance than 363 
previous tools including more complex measurements.8, 11, 13-15 This suggests that a 364 
detailed description of presented symptoms might predict later asthma equally well 365 
as more invasive methods, including blood eosinophilia or skin prick tests.8, 11, 13-15 366 
Seven of 10 predictors (including the 5 strongest) describe the symptoms: frequency 367 
of attacks, activity disturbance, shortness of breath, triggers (wheeze apart from 368 
colds, exercise, aeroallergens) and eczema. This is consistent with the old 369 
knowledge that frequent wheeze strongly predicts asthma persistence, 10, 43 and with 370 
our previous report, showing that frequency of wheeze predicted asthma nearly as 371 
well as the complicated API rule.19 In our tool, adding more symptoms (in addition to 372 
wheeze frequency) improved the performance (AUC after internal validation 0.74 for 373 
the tool vs. 0.57 for wheeze frequency only; Table E6). This shows that more 374 
detailed assessment of symptoms in pre-school children improves prediction of later 375 
asthma.  376 
Future research 377 
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To further evaluate the predictive performance of the proposed tool and assess its 378 
generalizability to other populations, external validation in independent samples is 379 
necessary.34 We therefore encourage the application and validation of this tool in 380 
ongoing epidemiological studies and clinical care (particularly primary care). Some 381 
earlier prediction models8, 9, 13 performed similarly in external populations, but their 382 
performance remained modest.15, 19, 37  383 
Compared to other prediction rules, our tool includes detailed description of symptom 384 
severity and pattern. This raises the possibility that further refinement in the 385 
description of preschool wheeze phenotype might improve precision of prediction of 386 
later asthma. Additional gains might be made by detailed assessment of age-related 387 
changes, physiological measurements (lung function, bronchial 388 
hyperresponsiveness, exhaled nitric oxide, atopy), environmental, socioeconomic 389 
and genetic risk factors.17 All this could, however, compromise the tool’s simplicity.  390 
Conclusions 391 
This tool represents a simple, low-cost and non-invasive method to predict the risk 392 
for later asthma in symptomatic preschool children, which is ready to be tested in 393 
other populations. 394 
Acknowledgements 395 
We thank all the children and parents of Leicestershire for participating in the study 396 
and we thank Kali Tal for her editorial assistance.  397 
Pescatore 19 
 
References 398 
1. Stevens CA, Turner D, Kuehni CE, Couriel JM, Silverman M. The economic 399 
impact of preschool asthma and wheeze. Eur Respir J 2003; 21:1000-6. 400 
2. Henderson J, Granell R, Heron J, Sherriff A, Simpson A, Woodcock A, et al. 401 
Associations of wheezing phenotypes in the first 6 years of life with atopy, 402 
lung function and airway responsiveness in mid-childhood. Thorax 2008; 403 
63:974-80. 404 
3. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. 405 
Asthma and wheezing in the first six years of life. The Group Health Medical 406 
Associates. N Engl J Med 1995; 332:133-8. 407 
4. Spycher BD, Silverman M, Brooke AM, Minder CE, Kuehni CE. Distinguishing 408 
phenotypes of childhood wheeze and cough using latent class analysis. Eur 409 
Respir J 2008; 31:974-81. 410 
5. Spycher BD, Silverman M, Kuehni CE. Phenotypes of childhood asthma: are 411 
they real? Clin Exp Allergy 2010; 40:1130-41. 412 
6. Caudri D, Wijga AH, Smit HA, Koppelman GH, Kerkhof M, Hoekstra MO, et al. 413 
Asthma symptoms and medication in the PIAMA birth cohort: evidence for 414 
under and overtreatment. Pediatr Allergy Immunol 2011; 22:652-9. 415 
7. Robertson CF, Price D, Henry R, Mellis C, Glasgow N, Fitzgerald D, et al. 416 
Short-course montelukast for intermittent asthma in children: a randomized 417 
controlled trial. Am J Respir Crit Care Med 2007; 175:323-9. 418 
8. Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to 419 
define risk of asthma in young children with recurrent wheezing. Am J Respir 420 
Crit Care Med 2000; 162:1403-6. 421 
Pescatore 20 
 
9. Caudri D, Wijga A, CM AS, Hoekstra M, Postma DS, Koppelman GH, et al. 422 
Predicting the long-term prognosis of children with symptoms suggestive of 423 
asthma at preschool age. J Allergy Clin Immunol 2009; 124:903-10 e1-7. 424 
10. Devulapalli CS, Carlsen KC, Haland G, Munthe-Kaas MC, Pettersen M, 425 
Mowinckel P, et al. Severity of obstructive airways disease by age 2 years 426 
predicts asthma at 10 years of age. Thorax 2008; 63:8-13. 427 
11. Eysink PE, ter Riet G, Aalberse RC, van Aalderen WM, Roos CM, van der 428 
Zee JS, et al. Accuracy of specific IgE in the prediction of asthma: 429 
development of a scoring formula for general practice. Br J Gen Pract 2005; 430 
55:125-31. 431 
12. Korppi M. Asthma predictive factors in infants with bronchiolitis: asthma risk at 432 
13-20 years of age. Eur Respir J 2010; 36:221-2. 433 
13. Kurukulaaratchy RJ, Matthews S, Holgate ST, Arshad SH. Predicting 434 
persistent disease among children who wheeze during early life. Eur Respir J 435 
2003; 22:767-71. 436 
14. Lodrup Carlsen KC, Soderstrom L, Mowinckel P, Haland G, Pettersen M, 437 
Munthe Kaas MC, et al. Asthma prediction in school children; the value of 438 
combined IgE-antibodies and obstructive airways disease severity score. 439 
Allergy 2010; 65:1134-40. 440 
15. Matricardi PM, Illi S, Keil T, Wagner P, Wahn U, Lau S. Predicting persistence 441 
of wheezing: one algorithm does not fit all. Eur Respir J 2010; 35:701-3. 442 
16. Balemans WA, van der Ent CK, Schilder AG, Sanders EA, Zielhuis GA, 443 
Rovers MM. Prediction of asthma in young adults using childhood 444 
characteristics: Development of a prediction rule. J Clin Epidemiol 2006; 445 
59:1207-12. 446 
Pescatore 21 
 
17. Savenije OE, Kerkhof M, Koppelman GH, Postma DS. Predicting who will 447 
have asthma at school age among preschool children. J Allergy Clin Immunol 448 
2012; 130:325-31. 449 
18. Corrao WM, Braman SS, Irwin RS. Chronic cough as the sole presenting 450 
manifestation of bronchial asthma. N Engl J Med 1979; 300:633-7. 451 
19. Leonardi NA, Spycher BD, Strippoli MP, Frey U, Silverman M, Kuehni CE. 452 
Validation of the Asthma Predictive Index and comparison with simpler clinical 453 
prediction rules. J Allergy Clin Immunol 2011; 127:1466-72 e6. 454 
20. Steyerberg E. Clinical prediction models: a practical approach to 455 
development, validation, and updating: Springer Verlag; 2009. 456 
21. Kuehni CE, Brooke AM, Strippoli MP, Spycher BD, Davis A, Silverman M. 457 
Cohort profile: the Leicester respiratory cohorts. Int J Epidemiol 2007; 36:977-458 
85. 459 
22. Dogaru CM, Strippoli MP, Spycher BD, Frey U, Beardsmore CS, Silverman M, 460 
et al. Breastfeeding and lung function at school age: does maternal asthma 461 
modify the effect? Am J Respir Crit Care Med 2012; 185:874-80. 462 
23. Spycher BD, Silverman M, Egger M, Zwahlen M, Kuehni CE. Routine 463 
vaccination against pertussis and the risk of childhood asthma: a population-464 
based cohort study. Pediatrics 2009; 123:944-50. 465 
24. Bisgaard H, Bonnelykke K. Long-term studies of the natural history of asthma 466 
in childhood. J Allergy Clin Immunol 2010; 126:187-97; quiz 98-9. 467 
25. Frank PI, Morris JA, Hazell ML, Linehan MF, Frank TL. Long term prognosis 468 
in preschool children with wheeze: longitudinal postal questionnaire study 469 
1993-2004. BMJ 2008; 336:1423-6. 470 
Pescatore 22 
 
26. Lowe L, Custovic A, Woodcock A. Childhood asthma. Curr Allergy Asthma 471 
Rep 2004; 4:159-65. 472 
27. Matricardi PM, Illi S, Gruber C, Keil T, Nickel R, Wahn U, et al. Wheezing in 473 
childhood: incidence, longitudinal patterns and factors predicting persistence. 474 
Eur Respir J 2008; 32:585-92. 475 
28. Midodzi WK, Rowe BH, Majaesic CM, Saunders LD, Senthilselvan A. 476 
Predictors for wheezing phenotypes in the first decade of life. Respirology 477 
2008; 13:537-45. 478 
29. Piippo-Savolainen E, Korppi M. Wheezy babies--wheezy adults? Review on 479 
long-term outcome until adulthood after early childhood wheezing. Acta 480 
Paediatr 2008; 97:5-11. 481 
30. Sherriff A, Peters TJ, Henderson J, Strachan D. Risk factor associations with 482 
wheezing patterns in children followed longitudinally from birth to 3(1/2) years. 483 
Int J Epidemiol 2001; 30:1473-84. 484 
31. Van Bever HP, Desager KN, Hagendorens M. Critical evaluation of prognostic 485 
factors in childhood asthma. Pediatr Allergy Immunol 2002; 13:77-83. 486 
32. Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized 487 
Linear Models via Coordinate Descent. J Stat Softw 2010; 33:1-22. 488 
33. Tibshirani R. Regression shrinkage and selection via the lasso. Journal of the 489 
Royal Statistical Society. Series B (Methodological) 1996:267-88. 490 
34. Harrell F. Regression modeling strategies: with applications to linear models, 491 
logistic regression, and survival analysis: Springer; 2001. 492 
35. Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of 493 
goodness-of-fit tests for the logistic regression model. Stat Med 1997; 16:965-494 
80. 495 
Pescatore 23 
 
36. Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3:32-5. 496 
37. Rodriguez-Martinez CE, Sossa-Briceno MP, Castro-Rodriguez JA. 497 
Discriminative properties of two predictive indices for asthma diagnosis in a 498 
sample of preschoolers with recurrent wheezing. Pediatr Pulmonol 2011; 499 
46:1175-81. 500 
38. Austin PC, Tu JV. Automated variable selection methods for logistic 501 
regression produced unstable models for predicting acute myocardial 502 
infarction mortality. J Clin Epidemiol 2004; 57:1138-46. 503 
39. Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F, et al. 504 
International Study of Asthma and Allergies in Childhood (ISAAC): rationale 505 
and methods. Eur Respir J 1995; 8:483-91. 506 
40. Strippoli MP, Silverman M, Michel G, Kuehni CE. A parent-completed 507 
respiratory questionnaire for 1-year-old children: repeatability. Arch Dis Child 508 
2007; 92:861-5. 509 
41. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. 510 
Interpretative strategies for lung function tests. Eur Respir J 2005; 26:948-68. 511 
42 Galant SP, Morphew T, Amaro S, Liao O. Value of the bronchodilator 512 
response in assessing controller naive asthmatic children. J Pediatr 2007; 513 
151:457-62, 62 e1.43. Phelan PD, Robertson CF, Olinsky A. The 514 
Melbourne Asthma Study: 1964-1999. J Allergy Clin Immunol 2002; 109:189-515 
94. 516 
 517 
 518 
 519 
  520 
Pescatore 24 
 
Table I. Characteristics of the study population (N=1226) at baseline, 
by development of asthma 5 years later* 
  5 yrs later: 5 yrs later:  
 Asthma    
(n=345) 
No Asthma   
(n=881) 
 
n (%) n (%) p-value† 
Demographic and perinatal data         
Male 224 (64.9) 454 (51.5) <0.001 
Age (years): 1 85 (24.6) 251 (28.5) 0.388 
2 204 (59.1) 498 (56.5) 
3 56 (16.2) 132 (15.0) 
Gestational age <37 weeks 35 (10.1) 49 (5.6) 0.006 
Birth weight <2500 g 41 (11.9) 68 (7.7) 0.025 
Wheeze-related symptoms‡ 
Current wheeze 272 (78.8) 425 (48.2) <0.001 
Wheeze without colds 127 (36.8) 95 (10.8) <0.001 
Frequency of attacks: 0 81 (23.5) 476 (54.0) <0.001 
1-3 111 (32.2) 281 (31.9) 
4-12 117 (33.9) 106 (12.0) 
>12 36 (10.4) 18 (2.0) 
Activity disturbance: no 141 (40.9) 649 (73.7) <0.001 
little 129 (37.4) 185 (21.0) 
moderate 57 (16.5) 39 (4.4) 
a lot 18 (5.2) 8 (0.9) 
Shortness of breath: never 129 (37.4) 668 (75.8) <0.001 
sometimes 166 (48.1) 190 (21.6) 
always 50 (14.5) 23 (2.6) 
Exercise-related wheeze/cough§ 196 (56.8) 286 (32.5) <0.001 
Aeroallergen-related wheeze/cough 52 (15.1) 37 (4.2) <0.001 
Other symptoms‡ 
Cough without colds 233 (67.5) 536 (60.8) 0.030 
Duration of colds (weeks): <1 75 (21.7) 203 (23.0) 0.194 
1-2 198 (57.4) 533 (60.5) 
>2 72 (20.9) 145 (16.5) 
Nasal symptoms 186 (53.9) 350 (39.7) <0.001 
Eczema (ever) 190 (55.1) 343 (38.9) <0.001 
Parental history 
Wheeze, asthma or 
bronchitis: none 142 (41.2) 499 (56.6) <0.001 
father 68 (19.7) 136 (15.4) 
mother 85 (24.6) 182 (20.7) 
both 50 (14.5) 64 (7.3) 
Hay fever: none 152 (44.1) 474 (53.8) 0.001 
father 56 (16.2) 144 (16.3) 
mother 93 (27.0) 203 (23.0) 
  both 44 (12.8) 60 (6.8)   
* This table includes all predictors that were selected for the main model 
† Fisher's exact test 
‡ During the last 12 months 
§ Wheeze or cough with running, playing, laughing or crying 
 521 
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Table II. Important factors for prediction of asthma at school age in 
symptomatic preschool children (selected by penalized logistic 
regression) 
  OR§ Regression 
coefficient 
(RC) 
Simpli-
fied 
RC* 
Order of 
inclusion 
      Main 
model 
Tool   
Demographic and perinatal data 
Male 1.48 0.394 1 9 
Age: >1 year 1.19 0.171 1 16 
Gestational age <37 weeks 1.11 0.108 18 
Birthweight <2500g 1.17 0.154 17 
Wheeze-related symptoms† 
Current wheeze 1.18 0.163 13 
Wheeze without colds 1.40 0.337 1 3 
Frequency of attacks: >3 1.65 0.500 2 2 
Activity 
disturbance: any 1.28 0.243 1 4 
moderate or a lot 1.16 0.144 7 
a lot 1.63 0.491 1 13 
Shortness of breath: 
sometimes or 
always 1.98 0.684 2 1 
always 1.56 0.442 1 6 
Exercise-related wheeze/cough‡ 1.26 0.233 1 5 
Aeroallergen-related wheeze/cough 1.22 0.198 1 10 
Other symptoms† 
Cough without colds 1.09 0.086 18 
Duration of colds: at least 1week 0.97 -0.031 22 
Nasal symptoms 1.17 0.157 12 
Eczema (ever) 1.52 0.420 1 7 
Parental history 
Wheeze, asthma or 
bronchitis: mother or father 1.23 0.203 1 10 
both parents 1.26 0.235 1 13 
Hay fever: mother or father 1.03 0.025 21 
both parents 1.12 0.110 18 
Number of binary predictors 22 22 13 22 
Number of variables 17 17 10 17 
* RC of the main model multiplied by 3 and rounded to the nearest integer 
(simplification approach where the number of variables was substantially reduced 
without relevant decrease in predictive performance) 
† During the last 12 months 
‡ Wheeze or cough with running, playing, laughing or crying 
§ Confidence intervals for the ORs are not provided because OR estimates result from 
penalized logistic regression which is primarily a method for variable selection rather 
than for statistical inference. Estimates are deliberately biased toward null with the 
benefit of reducing their variance and improving overall prediction. Confidence 
intervals are misleading in this context. 
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Table III. Comparison of four asthma prediction tools for preschool children 524 
  Leicester (present study) 
(Leicestershire Respiratory Cohort Studies) 
Tucson (API)8* 
Tucson Children’s Respiratory Study 
IoWBC13 
Isle of Wight Birth Cohort 
PIAMA9 
Prevention and Incidence of Asthma 
and Mite Allergy 
N (included in analysis) 1226 776 336 2054 
Inclusion criteria     
 Age (y) 1-3 2-3 4 1-4 
 Symptoms 
 
Health care visit due to respiratory 
problems plus at least one of the following 
symptoms in the past 12 months: 
Wheeze, cough without colds, cough at 
night 
Entire cohort (including a majority of 
children without symptoms) 
Wheeze at ages 1,2 and 4 yrs 
 
Wheeze or cough at night without colds 
(or both) in the past 12 months 
Outcome definition     
 Age (y) 6-8  8 10 7-8 
 Prediction interval (y) 4-5 5 6 3-7 
 Criteria 
 
 
Wheeze plus asthma medication (past 12 
mo) 
 
Doctor’s diagnosis of asthma plus 
current wheeze, or more than 3 wheeze 
episodes (past 12 mo) 
Current wheeze  At ages 7 and 8y: Current wheeze or 
prescription of inhaled corticosteroids 
or doctor's diagnosis of asthma (past 12 
mo) 
 Outcome prevalence 28.1 % 13.7% 37.2% 11.7% 
Predictor variables included in tool Male sex,  
Age: >1y,  
wheeze without colds,  
frequent wheeze, 
activity disturbance, 
shortness of breath,  
exercise-related wheeze/cough†,  
aeroallergen-related wheeze/cough,  
eczema,  
parental asthma or wheeze bronchitis 
Wheeze, 
frequent wheeze‡ , 
wheeze without colds, 
eczema, 
parental asthma,  
blood eosinophilia, 
allergic rhinitis 
Family history of asthma,  
recurrent chest infections (at 2yrs),  
skin prick test positivity (at 4yrs),  
nasal symptoms (at 1yr) 
 
Male sex,  
post term delivery,  
wheeze/dyspnea without colds,  
frequent wheeze,  
eczema, 
respiratory infections,  
inhalation medication (parents), 
parental education 
Method used to derive tool Penalized logistic regression The combination of predictors was 
chosen that yielded the highest PPV and 
specificity  
Stepwise backward logistic regression Stepwise backward logistic regression 
Performance measures§ Score-cutoff: ≥5 Loose API  Score-cutoff: ≥3 Score-cutoff: ≥20 
 Youden index36 0.43 0.32 0.38 0.36 
 Sensitivity (%) 72 51  53  60 
 Specificity (%) 71 81 85 76  
 PPV (%) 49 29 68 23 
 NPV (%) 86 91 74 94 
API, Asthma Predictive Index; PPV, positive predictive value; NPV, negative predictive value. 525 
* To have a prediction interval comparable to the one in our tool, we focused here on the API for prediction at 8 yrs 526 
† Wheeze or cough with running, playing, laughing or crying 527 
‡ This variable is only part of the stringent API, but not of the loose API 528 
§ Reported for cut-off where sum of sensitivity and specificity pair was maximal. It is possible that a higher sum of sensitivity and specificity exists at a cut-off point that was not reported in the respective studies. 529 
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Figure legends 530 
 531 
Fig 1. Wheeze, cough and health care visits in 1 to 3 year-old children. 532 
Proportional Venn diagram for children aged 1 to 3 years, showing frequency of 533 
health care visits due to wheeze or cough, current wheeze and chronic cough (cough 534 
without colds or cough at night). The shaded grey represents our study population. 535 
 536 
Fig 2. Calibration plot of main model (assessed in leave-one out cross-537 
validation). Children are grouped into deciles of their predicted probability. The 538 
average predicted probability for later asthma among children within each decile is 539 
plotted against the actual observed frequency (prevalence) of asthma in that group. 540 
As a visual aid a smoothing technique (locally-weighted polynomial regression) was 541 
applied to these data.  542 
The straight line represents perfect calibration.  543 
 544 
Fig 3. Asthma prediction tool. For any 1-3-year-old child seeking health care due 545 
to wheeze or cough the applicable predictors are summed to a total score in the 546 
upper part of the figure. The estimated probability of having asthma 5 years later is 547 
given below for different total scores. 548 
 549 
Fig 4. Receiver operating characteristic (ROC) curves for the main asthma 550 
prediction model and for the prediction tool.  551 
The dots represent sensitivity and specificity for different cutoff-values of the 552 
prediction tool. 553 
 554 
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Details of statistical methods 26 
Development of the main prediction model 27 
We used the R package glmnet to fit the penalized logistic regression. The 28 
parameter alpha was set to 1 so that only a LASSO type penalty was included. This 29 
tends to retain only the most influential predictors. The parameter lambda, which 30 
determines the magnitude of the penalty was set to a value that maximized the area 31 
under the receiver operating characteristic curve of resulting predictions in 10-fold 32 
cross-validation1. All potential predictors with more than 2 response categories were 33 
coded as binary variables. If the original categories were ordered, these 34 
dichotomous variables represented all possible cut-off points separating lower from 35 
higher categories.  For instance, frequency of wheezing episodes in the past 12 36 
months (0, 1-3, 4-12, >12) was coded into 3 binary variables indicating >0, >3, and 37 
>12 episodes respectively. This procedure resulted in 38 binary variables entering 38 
variable selection.  39 
Confidence intervals for the ORs are not provided because OR estimates result from 40 
penalized logistic regression which is primarily a method for variable selection rather 41 
than for statistical inference. Estimates are deliberately biased toward null with the 42 
benefit of reducing their variance and improving overall prediction. Confidence 43 
intervals are misleading in this context.  44 
Data were prepared using Stata 11.0 and analysed using R version 2.12.2. We used 45 
the R package ROCR to assess discrimination and the functions hosmerlem and 46 
val.prob.ci to assess calibration2. 47 
 48 
Clinical prediction tool 49 
To simplify our model to a practical tool, we considered three different approaches: 50 
a) multiplying regression coefficients by factors 10, 5 and 3 and rounding them to the 51 
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nearest integer;20 b) setting the penalty of the LASSO-penalized logistic regression 52 
so that only a few important predictors (5 or 3) were retained, and c) considering a 53 
model with frequency of wheeze as the only predictor.19 All these approaches aimed 54 
to reduce the number of variables while maintaining a comparable predictive 55 
performance. 56 
In Table E7 the performance of these tools are compared with the main model in 57 
sample (sample used for model development) and by internal validation (see below). 58 
In a final step, we recalibrated the probabilities for later asthma of the preferred tool 59 
by re-running a logistic regression of the outcome on simplified scores. 60 
 61 
Internal validation 62 
To assess the reliability of our result of model performance within our study sample 63 
(i.e. to test its repeatability within our development sample) we tested our model in 64 
leave-one-out cross-validation. The first step in this technique is to omit the first of 65 
total n observations and to use the remaining n-1 observations from the entire study 66 
sample to develop a new model. Using this new model, the probability for later 67 
asthma is estimated for the one observation left out before. In total, this procedure is 68 
repeated n times, each time omitting an observation that has not previously been left 69 
out. In the end, internal validity of the model is tested based on these estimated 70 
probabilities.  71 
Because the purpose was to test the main model’s predictive performance and not 72 
how the method performs (including variable selection), we chose leave-one-out 73 
cross-validation as an internal validation technique that aims to fit models which are 74 
very similar to the main model. Other approaches, such as bootstrapping, would 75 
result in fitting models that are less similar to the main model, and thus would have 76 
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tested the repeatability of the method (variable selection approach and estimation of 77 
regression coefficients) rather than have validated the main model itself.  78 
 79 
 80 
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Table E1. Characteristics of the study population (N=1226) at baseline by development of 
asthma 5 years later (all potential predictors considered in the analysis) 
5 yrs later: 5 yrs later:  
   Total 
study 
population 
(N=1226) 
Asthma    
(N=345) 
No 
Asthma    
(N=881) 
  
Question 
number*  n  (%) n (%) n (%)   p-value†
Demographic and perinatal data 
Male 678 (55.3) 224 (64.9) 454 (51.5) <0.001 
Age (years) 1 336 (27.4) 85 (24.6) 251 (28.5) 0.388 
2 702 (57.3) 204 (59.1) 498 (56.5) 
3 188 (15.3) 56 (16.2) 132 (15.0) 
Gestational age <37 weeks 84 (6.9) 35 (10.1) 49 (5.6) 0.006 
Birth weight <2500 g 109 (8.9) 41 (11.9) 68 (7.7) 0.025 
South Asian ethnicity (versus white) 316 (25.8) 78 (22.6) 238 (27.0) 0.127 
Wheeze-related symptoms‡ 
8 Current wheeze 697 (56.9) 272 (78.8) 425 (48.2) <0.001 
9 Wheeze without colds 222 (18.1) 127 (36.8) 95 (10.8) <0.001 
10 Frequency of attacks: 0 557 (45.4) 81 (23.5) 476 (54.0) <0.001 
1-3 392 (32.0) 111 (32.2) 281 (31.9) 
4-12 223 (18.2) 117 (33.9) 106 (12.0) 
>12 54 (4.4) 36 (10.4) 18 (2.0) 
11 Activity disturbance: no 790 (64.4) 141 (40.9) 649 (73.7) <0.001 
little 314 (25.6) 129 (37.4) 185 (21.0) 
moderate 96 (7.8) 57 (16.5) 39 (4.4) 
a lot 26 (2.1) 18 (5.2) 8 (0.9) 
12 Shortness of breath: never 797 (65.0) 129 (37.4) 668 (75.8) <0.001 
sometimes 356 (29.0) 166 (48.1) 190 (21.6) 
always 73 (6.0) 50 (14.5) 23 (2.6) 
13 Sleep disturbance: never 790 (64.4) 148 (42.9) 642 (72.9) <0.001 
<1 269 (21.9) 122 (35.4) 147 (16.7) 
>=1 167 (13.6) 75 (21.7) 92 (10.4) 
14 Exercise-related wheeze/cough§ 482 (39.3) 196 (56.8) 286 (32.5) <0.001 
14 Aeroallergen-related wheeze/cough 89 (7.3) 52 (15.1) 37 (4.2) <0.001 
14 Food-related wheeze/cough 186 (15.2) 54 (15.7) 132 (15.0) 0.791 
Other symptoms‡ 
15 Cough without colds 769 (62.7) 233 (67.5) 536 (60.8) 0.030 
16 Cough at night 631 (51.5) 190 (55.1) 441 (50.1) 0.127 
17 Frequency of colds: <4 447 (36.5) 101 (29.3) 346 (39.3) 0.001 
4-6 461 (37.6) 134 (38.8) 327 (37.1) 
>6 318 (25.9) 110 (31.9) 208 (23.6) 
18 Duration of colds (weeks): <1 278 (22.7) 75 (21.7) 203 (23.0) 0.194 
1-2 731 (59.6) 198 (57.4) 533 (60.5) 
>2 217 (17.7) 72 (20.9) 145 (16.5) 
19 Ear infection(s): 0 599 (48.9) 151 (43.8) 448 (50.9) 0.020 
1 351 (28.6) 99 (28.7) 252 (28.6) 
>1 276 (22.5) 95 (27.5) 181 (20.5) 
20 Nasal symptoms 536 (43.7) 186 (53.9) 350 (39.7) <0.001 
21 Snoring 880 (71.8) 267 (77.4) 613 (69.6) 0.006 
22 Eczema (ever) 533 (43.5) 190 (55.1) 343 (38.9) <0.001 
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Parental history  
23/24 
Wheeze, asthma or 
bronchitis: none 641 (52.3) 142 (41.2) 499 (56.6) <0.001 
father 204 (16.6) 68 (19.7) 136 (15.4) 
mother 267 (21.8) 85 (24.6) 182 (20.7) 
both 114 (9.3) 50 (14.5) 64 (7.3) 
23/24 Hay fever: none 626 (51.1) 152 (44.1) 474 (53.8) 0.001 
father 200 (16.3) 56 (16.2) 144 (16.3) 
mother 296 (24.1) 93 (27.0) 203 (23.0) 
    both 104 (8.5) 44 (12.8) 60 (6.8)     
* See Online Repository: Original questions used in questionnaires 
† Fisher's exact test 
‡ During the last 12 months 
§ Wheeze or cough with running, playing, laughing or crying 
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Table E2. Characteristics of children at baseline, by availability of 
follow-up information (N=2444) 
  Follow-up 
information 
available     
(N=1226) 
Follow-up 
information 
not 
available     
(N=1218) 
  
  n (%) n (%)   p-value* 
Demographic and perinatal data 
Male 678 (55.3) 633 (52.0) 0.105 
Gestational age <37 weeks 84 (6.9) 86 (7.1) 0.874 
Birth weight <2500 g 109 (8.9) 86 (7.1) 0.101 
South Asian ethnicity (versus white) 316 (25.8) 386 (31.7) 0.001 
Wheeze-related symptoms† 
Current wheeze 697 (56.9) 762 (62.6) 0.004 
Wheeze without colds 222 (18.1) 272 (22.3) 0.010 
Frequency of attacks: 0 557 (45.4) 482 (39.6) 0.012 
1-3 392 (32.0) 419 (34.4) 
4-12 223 (18.2) 269 (22.1) 
>12 54 (4.4) 48 (3.9) 
Activity disturbance: no 790 (64.4) 725 (59.5) 0.044 
little 314 (25.6) 371 (30.5) 
moderate 96 (7.8) 91 (7.5) 
a lot 26 (2.1) 31 (2.5) 
Shortness of breath: never 797 (65.0) 749 (61.5) 0.193 
sometimes 356 (29.0) 387 (31.8) 
always 73 (6.0) 82 (6.7) 
Sleep disturbance: never 790 (64.4) 728 (59.8) 0.059 
<1 269 (21.9) 304 (25.0) 
>=1 167 (13.6) 186 (15.3) 
Exercise-related wheeze/cough‡ 482 (39.3) 531 (43.6) 0.033 
Aeroallergen-related wheeze/cough 89 (7.3) 104 (8.5) 0.261 
Food-related wheeze/cough 186 (15.2) 196 (16.1) 0.540 
Other symptoms† 
Cough without colds 769 (62.7) 798 (65.5) 0.152 
Cough at night 631 (51.5) 612 (50.2) 0.571 
Frequency of colds: <4 447 (36.5) 420 (34.5) 0.498 
4-6 461 (37.6) 484 (39.7) 
>6 318 (25.9) 314 (25.8) 
Duration of colds (weeks): <1 278 (22.7) 268 (22.0) 0.897 
1-2 731 (59.6) 737 (60.5) 
>2 217 (17.7) 213 (17.5) 
Ear infection(s): 0 599 (48.9) 613 (50.3) 0.481 
1 351 (28.6) 322 (26.4) 
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>1 276 (22.5) 283 (23.2) 
Nasal symptoms 536 (43.7) 569 (46.7) 0.143 
Snoring 880 (71.8) 877 (72.0) 0.928 
Eczema (ever) 533 (43.5) 548 (45.0) 0.464 
Parental history  
Wheeze, asthma or 
bronchitis: none 641 (52.3) 647 (53.1) 0.581 
father 204 (16.6) 178 (14.6) 
mother 267 (21.8) 276 (22.7) 
both 114 (9.3) 117 (9.6) 
Hay fever: none 626 (51.1) 646 (53.0) 0.702 
father 200 (16.3) 199 (16.3) 
mother 296 (24.1) 271 (22.2) 
  both 104 (8.5) 102 (8.4)     
* Fisher's exact test 
† During the last 12 months 
‡ Wheeze or cough with running, playing, laughing or crying 
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Table E3. Sensitivity analysis I: Testing performance of main asthma prediction model in alternative 
study populations 
Baseline criteria Outcome definition
1-3 year-olds 5 yrs later 
Study population 
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N n (%) Brier (scaled) AUC*
Total Outcome  
P0 (used for main model)    1226 345 (28.1) 0.23 0.78 
P1     769 285 (37.1) 0.21 0.77 
P2   697 272 (39.0) 0.22 0.77 
P3    1239 331 (26.7) 0.25 0.80 
P4     1053 71 (6.7) -0.51† 0.87 
Baseline and outcome criteria refer to the past 12 months, if not otherwise stated 
*Area under receiver operating characteristic curve   
† The negative scaled Brier score is due to the large difference in the prevalence of the outcome in P0 and P4. A simple 
recalibration without changing the score would lead to a scaled Brier score of 0.24 
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Table E4. Sensitivity analysis II: Testing performance of newly developed asthma prediction models based on 
alternative study populations 
       
 Baseline criteria Outcome definition
 1-3 year-olds 5 yrs later 
Study population 
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No. of binary 
predictors in 
the model N n (%) Brier (scaled) AUC*
Total Outcome
P0 (used for main model)    22 1226 345 (28.1) 0.23 0.78 
P1     25 769 285 (37.1) 0.22 0.77 
P2   23 697 272 (39.0) 0.23 0.78 
P3    26 1239 331 (26.7) 0.26 0.81 
P4     20 1053 71 (6.7) 0.28 0.89 
Baseline and outcome criteria refer to the past 12 months, if not otherwise stated 
*Area under receiver operating characteristic curve 
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TABLE E5. Selected predictors in sensitivity analysis II and corresponding 
ORs 
Main model* New models             (alternative populations) 
P1† P2‡ P3§ P4ǁ 
  Odds Ratio 
(OR) OR OR OR OR 
Demographic and perinatal data 
Male 1.48 1.43 1.49 1.68 1.00 
Age (years) ≥2 1.19 1.53 1.51 1.28 1.00 
3 1.00 1.00 1.01 1.06 0.95 
Gestational age <37 weeks 1.11 1.13 1.00 1.16 1.00 
Birth weight <2500 g 1.17 1.18 1.28 1.34 1.00 
South Asian ethnicity (versus white) 1.00 1.00 1.00 1.00 0.53 
Wheeze-related symptoms¶ 
Current wheeze 1.18 1.00 1.00 1.59 1.46 
Wheeze without colds 1.40 1.55 1.45 1.42 2.11 
Frequency of attacks ≥1 1.00 1.00 1.00 1.05 1.00 
>3 1.65 1.53 1.60 1.37 1.16 
>12 1.00 1.00 1.00 1.00 2.10 
Activity disturbance any 1.28 1.30 1.25 1.28 1.49 
moderate or a lot 1.16 1.31 1.17 1.14 1.00 
a lot 1.63 1.94 1.87 1.81 2.18 
Shortness of breath sometimes or always 1.98 1.90 1.91 1.84 2.06 
always 1.56 1.40 1.41 2.10 2.70 
Sleep disturbance ≥1/week 1.00 1.00 1.00 1.10 1.00 
>1/week 1.00 1.00 1.00 1.00 1.20 
Exercise-related wheeze/cough** 1.26 1.09 1.15 1.40 1.27 
Aeroallergen-related wheeze/cough 1.22 1.05 1.04 1.33 1.00 
Food-related wheeze/cough 1.00 1.03 1.02 0.97 1.00 
Other symptoms¶ 
Cough without colds 1.09 1.10 1.07 1.16 1.37 
Cough at night 1.00 1.12 1.13 1.06 1.00 
Frequency of colds >3 1.00 1.00 1.00 1.00 1.06 
>6 1.00 0.97 1.00 1.00 1.00 
Duration of colds 
(weeks) ≥1 0.97 0.89 0.90 0.80 1.00 
>2 1.00 1.00 1.00 1.00 1.00 
Ear infection(s) ≥1 1.00 1.13 1.00 1.00 1.00 
>1 1.00 1.00 1.00 1.00 1.00 
Nasal symptoms 1.17 1.14 1.13 1.18 1.14 
Snoring 1.00 1.00 1.00 1.00 1.00 
Eczema (ever) 1.52 1.42 1.50 1.39 1.62 
Parental history  
Wheeze or bronchitis mother or father 1.23 1.14 1.06 1.45 1.07 
mother or both 1.00 1.00 1.00 1.00 1.00 
both parents 1.26 1.57 1.36 1.39 2.02 
Hay fever mother or father 1.03 1.00 1.00 1.00 1.09 
mother or both 1.00 1.05 1.01 1.00 1.00 
Pescatore 12 
 
both parents 1.12 1.28 1.37 1.41 1.34 
Baseline and outcome criteria refer to the past 12 months, if not otherwise stated 
* Inclusion criteria: 1-3 year-olds with health care visit plus either wheeze or cough without 
colds or cough at night; 
Outcome: Wheeze plus asthma medication at age 6-8 yrs 
† Inclusion criterion: 1-3 year-olds with wheeze; Outcome: same as in main model 
‡ Inclusion criteria: 1-3 year-olds with health care visit plus wheeze; Outcome: same as in 
main model 
§ Inclusion criteria: same as in main model; Outcome: Current wheeze plus doctor's 
diagnosis of asthma (ever) at age 6-8 yrs 
ǁInclusion criteria: same as in main model; Outcome: >4 episodes of wheeze and using 
inhaled corticosteroids 
¶ During the last 12 months 
**Wheeze or cough with running, playing, laughing or crying 
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Table E6. Predictive performance of simplified versions of the main asthma prediction model 
No. of binary 
predictors in 
the model 
Brier score (scaled) AUC* 
Simplification approach before valǁ after val¶ before valǁ after val¶ 
Main model no simplification 22 0.23 0.20 0.78 0.76 
Rounded 
model† 
factor 10 20 0.23 0.19 0.78 0.75 
factor 5 19 0.23 0.21 0.78 0.77 
factor 3†† 13 0.22 0.16 0.78 0.74 
Reduced model first five predictors only‡ 5 0.14 0.13 0.75 0.64 
first three predictors only§ 3 0.12 0.11 0.73 0.60 
Frequent wheeze only** 3 0.13 0.12 0.70 0.57 
* Area under receiver operating characteristics curve 
†: Using simplified regression coefficients of the model (regression coefficients of main model multiplied by 10, 
by 5 or by 3, respectively,  and rounded to the next integer) 
‡ Shortness of breath due to wheeze, frequent wheeze episodes (>3), wheeze without colds, activity disturbance 
due to wheeze; exercise-related wheeze/cough 
§ Shortness of breath due to wheeze, frequent wheeze episodes (>3), wheeze without colds 
ǁ Before internal validation: assessment using same sample as used to develop the model 
¶ After internal validation: assessment using leave-one-out crossvalidation 
** A 4-level variable coded as 3 binary dummy variables; analysis using logistic regression without penalization 
†† Preferred model 
Table E7. Performance measures of the prediction tool for different 
cutoff-values (calculated in sample used to develop the tool without 
crossvalidation) 
Score-cutoff Sensitivity Specificity PPV NPV LR+ LR- 
0 >0.99 <0.01 0.28 NA 1.00 * 
1 >0.99 0.02 0.29 0.95 1.02 0.12 
2 0.96 0.14 0.30 0.89 1.11 0.30 
3 0.91 0.37 0.36 0.92 1.45 0.23 
4 0.79 0.57 0.42 0.87 1.84 0.37 
5 0.72 0.71 0.49 0.86 2.47 0.40 
6 0.62 0.80 0.55 0.84 3.18 0.47 
7 0.52 0.88 0.62 0.82 4.19 0.55 
8 0.42 0.92 0.68 0.80 5.53 0.63 
9 0.33 0.96 0.77 0.79 8.32 0.70 
10 0.22 0.98 0.79 0.76 9.36 0.80 
11 0.13 0.99 0.80 0.74 10.45 0.88 
12 0.06 >0.99 0.83 0.73 12.77 0.95 
13 0.02 >0.99 0.89 0.72 20.43 0.98 
14 0.01 >0.99 >0.99 0.72 * 0.99 
15 <0.01 >0.99 NA 0.72 * >0.99 
PPV, positive predictive value; NPV, negative predictive value; LR+, likelihood ratio 
positive; LR-, likelihood ratio negative  
Sensitivity, Specificity, PPV, NPV: restricted to values between 0 and 1 
* Great uncertainty of estimate due to sensitivity and specificity close to 0 or 1 
Pescatore 14 
 
 102 
Table E8. Comparison of percentage change in FEV1 and MEF50 after bronchodilator 
administration by questionnaire-based outcome definitions assessed at the same time 
Outcome criteria Any asthma 
(current wheeze and asthma medication) 
Moderately severe asthma 
(>4 episodes of wheeze in the past 12 months 
and inhaled corticosteroids) 
Fulfilling 
outcome criteria 
Yes No Yes No 
NFEV1 111 340 30 389 
Mean % change 
in FEV1 after 
bronchodilator 
administration 
5.46 
95%CI=[3.58,7.34] 
2.59 
95%CI=[1.96,3.21] 
9.10 
95%CI=[3.74,14.45] 
2.76 
95%CI=[2.15,3.38] 
NMEF50 109 334 29 382 
Mean % change 
in MEF50 after 
bronchodilator 
administration 
16.66 
95%CI=[12.80,20.53] 
10.65 
95%CI=[8.75,12.54] 
18.60 
95%CI=[9.75,27.46] 
11.21 
95%CI=[9.39,13.03] 
FEV1,Forced expiratory volume in the 1st second; MEF50, maximal expiratory flow at 50% of vital capacity 103 
t-tests: any asthma: pFEV1=<0.001; pMEF50=0.003; moderately severe asthma: pFEV1<0.001; pMEF50=0.039; 104 
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Figure legends 117 
 118 
 119 
Fig E1. Original questions used to define inclusion criteria at baseline 120 
Fig E2. Original questions used to assess outcome at follow-up 121 
Fig E3. Original questions used as potential predictive factors 122 
 123 
No wheeze, no cough, 
no related health care 
visits
Chronic
cough
Current
wheeze
Health care
visits
1089 (18.5%)
522 (8.9%)
47
(0.8%)
484 (8.2%)1739 (29.6%)
985 (16.8%)
937 (15.9%)
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